300 Participants Needed

Dental Health Assessment for Esophageal Cancer

SM
LD
Overseen ByLuis Diaz, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Memorial Sloan Kettering Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The researchers are doing this study to find out more about what may lead to the loss of tooth enamel (the thin outer covering of the tooth) and how often it happens in people with esophagogastric cancer, colorectal cancer, pancreatic cancer, breast cancer, head and neck cancer, or non-small cell lung cancer, or a healthy volunteer.

Do I need to stop my current medications for this trial?

The trial protocol does not specify whether you need to stop taking your current medications.

What data supports the idea that Dental Health Assessment for Esophageal Cancer is an effective treatment?

The available research does not provide specific data supporting the effectiveness of Dental Health Assessment for Esophageal Cancer. Instead, it focuses on other treatments like surgery, chemotherapy, and radiation. These treatments, especially when combined, have shown some improvement in survival rates and resectability of tumors. However, there is no mention of Dental Health Assessment being used or evaluated for esophageal cancer in the provided research.12345

What safety data exists for intraoral cameras used in dental health assessments?

The provided research does not directly address safety data for intraoral cameras. However, it discusses their increasing use in dentistry, their role in remote risk assessment and monitoring of oral lesions, and their application in clinical photography. The studies focus on image quality, ease of use, and recommendations for effective use, but do not specifically mention safety concerns or data.678910

Is the treatment in the trial 'Dental Health Assessment for Esophageal Cancer' a promising treatment?

Yes, the treatment is promising because improving dental health can help reduce the risk of severe pneumonia after surgery for esophageal cancer, and it may also be linked to better overall outcomes for patients.711121314

Research Team

SM

Steven Maron, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

This study is for adults over 18 with esophagogastric cancer who can understand English or have translation services. They should be able to complete a survey and allow photos of their teeth, but those without teeth or major dental work on molars that affects enamel assessment cannot join.

Inclusion Criteria

Subject is willing and able to provide written informed consent
I am 18 years old or older.
Patients must be able to understand English language or have access to adequate translation services
See 2 more

Exclusion Criteria

I have never had cancer (other than skin cancer) and am not being evaluated for reflux.
I don't have molars or have had significant dental work on them.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dental Imaging and Survey

Participants complete a survey and undergo dental imaging; optional saliva sample collection for esophagogastric cancer patients

1-2 weeks
1 visit (in-person)

Follow-up

Participants are monitored for the incidence of dental erosions over a year

1 year

Treatment Details

Interventions

  • Intra-oral camera
  • MouthWatch intra-oral camera
  • Survey
Trial OverviewThe study aims to understand tooth enamel loss in people with various cancers including esophagogastric cancer. Participants will provide saliva samples, answer surveys about their oral health, and have pictures taken of their teeth using an intra-oral camera.
Participant Groups
3Treatment groups
Experimental Treatment
Group I: Patients diagnosed with esophagogastric cancerExperimental Treatment3 Interventions
Patients have completed the intervention once completing the survey, undergoing dental imaging and future patients will also provide an optional saliva sample.
Group II: Patients diagnosed with colorectal, pancreatic, breast, head and neck, or non-small cell lung cancerExperimental Treatment2 Interventions
Patients undergo consenting and dental imaging during their routine visits at MSK.
Group III: Healthy volunteers who have not been diagnosed with cancerExperimental Treatment2 Interventions
Healthy controls will be defined as those without a known or suspected invasive cancer history and excluding those undergoing a procedure for symptomatic reflux.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials
1,998
Recruited
602,000+

Findings from Research

In a study of 8,396 esophageal cancer patients, those receiving collaborative treatment across multiple institutions had a slightly lower adherence to guideline-recommended chemotherapy and radiation doses compared to those treated at a single institution.
Despite these differences, the rates of R0 resection and overall survival (90-day and 5-year) were similar between the two groups, suggesting that collaborative treatment is a viable option with manageable impacts on treatment quality.
Assessment of a collaborative treatment model for trimodal management of esophageal cancer.Udelsman, BV., Ermer, T., Ely, S., et al.[2023]
The implementation of a regional video Upper-GI multidisciplinary team meeting (uMDTM) significantly increased the number of patients discussed and involved a resection center more frequently, leading to more curative surgical interventions for esophageal cancer.
Overall survival rates for patients with esophageal cancer improved from 24% to 30% over three years after the uMDTM was implemented, indicating a positive impact on patient outcomes.
Implementation of a regional video multidisciplinary team meeting is associated with an improved prognosis for patients with oesophageal cancer A mixed methods approach.Luijten, JCHBM., Haagsman, VC., Luyer, MDP., et al.[2022]
Esophageal cancer is the most rapidly increasing cancer in the Western world, with a poor overall survival rate despite advancements in treatment, highlighting the need for improved therapeutic strategies.
Neoadjuvant chemoradiation followed by surgery may enhance resectability and overall survival, but only patients with a major histopathological response benefit, indicating the importance of developing predictive molecular markers to tailor treatments effectively.
Molecular response prediction in multimodality treatment for adenocarcinoma of the esophagus and esophagogastric junction.Lurje, G., Lenz, HJ.[2018]

References

Assessment of a collaborative treatment model for trimodal management of esophageal cancer. [2023]
Implementation of a regional video multidisciplinary team meeting is associated with an improved prognosis for patients with oesophageal cancer A mixed methods approach. [2022]
Molecular response prediction in multimodality treatment for adenocarcinoma of the esophagus and esophagogastric junction. [2018]
[Esophagus carcinoma: radical concepts]. [2008]
Combined modality therapy of esophageal cancer. [2019]
A systematic evaluation of intraoral cameras. [2015]
Intraoral Photography Recommendations for Remote Risk Assessment and Monitoring of Oral Mucosal Lesions. [2022]
Use of dental photography by general dental practitioners in Great Britain. [2018]
Clinical recommendations for the use of D-speed film, E-speed film, and xeroradiography. [2019]
Dental screenings using telehealth technology: a pilot study. [2006]
[Detection strategies and risk factors in oral cancers]. [2011]
Using NHANES oral health examination protocols as part of an esophageal cancer screening study conducted in a high-risk region of China. [2018]
Polish public caries prophylaxis programme for children aged 5, 7 and 15 years, implemented in the year 2011. [2019]
Esophageal Cancer Patients Have a High Incidence of Severe Periodontitis and Preoperative Dental Care Reduces the Likelihood of Severe Pneumonia after Esophagectomy. [2017]